 | Up a level |
Mc Laughlin, Anna M; Hess, Dagmar; Michelet, Robin; Colombo, Ilaria; Haefliger, Simon; Bastian, Sara; Rabaglio, Manuela; Schwitter, Michael; Fischer, Stefanie; Eckhardt, Katrin; Hayoz, Stefanie; Kopp, Christoph; Klose, Marian; Sessa, Cristiana; Stathis, Anastasios; Halbherr, Stefan; Huisinga, Wilhelm; Joerger, Markus; Kloft, Charlotte (2024). Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer chemotherapy and pharmacology, 94(3), pp. 349-360. Springer 10.1007/s00280-024-04679-z
Colombo, Ilaria; Koster, Kira-Lee; Holer, Lisa; Haefliger, Simon; Rabaglio, Manuela; Bastian, Sara; Schwitter, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Mc Laughlin, Anna M; Kloft, Charlotte; Klose, Marian; Halbherr, Stefan; Baumgartner, Christian; Sessa, Cristiana; Stathis, Anastasios; Hess, Dagmar; Joerger, Markus (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European journal of cancer, 201(113588), p. 113588. Elsevier 10.1016/j.ejca.2024.113588
Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung cancer, 156, pp. 91-99. Elsevier 10.1016/j.lungcan.2021.04.002
